Detailed price information for Biorestorative Therapies Inc (BRTX-Q) from The Globe and Mail including charting and trades.

Researchers at Tel Aviv University and the Sagol Center for Hyperbaric Medicine and Research at the Shamir Medical Center have demonstrated that hyperbaric oxygen therapy (HBOT) improves the condition ...

Repetitive transcranial magnetic stimulation offers rapid depression relief for patients unresponsive to conventional ...

Spanish colleagues and I just published an article entitled "Is Osteopathic Manipulative Treatment Clinically Superior to Sham or Placebo for Patients with Neck or Low-Back Pain? A Systematic Review ...

Trippy author Ernesto Londoño points out that supposedly ancient psychedelic rituals don't always lead to great outcomes.

The US Food and Drug Administration has FDA has granted marketing authorization to a form of light therapy as the first-ever ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

Reported Q3 worldwide revenue of EUR 13.1 million (USD 14.4 million), increasing 11.6% over Q3 2023Reported Q3 worldwide HIFU revenue of ...

The Food and Drug Administration will allow a new device to be marketed as a treatment for dry age-related macular degeneration.

A combination of two “active” therapies may help slow cognitive decline in older adults, especially those with a type of severe depression and a genetic risk of Alzheimer's, a study indicates.

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).